Eversense Distribution Partners

Germany

Ascensia Diabetes Care Deutschland GmbH
51355 Leverkusen
Deutschland
0800 5088844
www.ascensia.com/eversense

Israel
DYN Diagnostics Ltd.
7 Ha'eshel St. P.O. Box 3063
Caesarea Industrial Park 3079504, Israel
www.dyndiabetes.co.il
04-6175390

Italy
Ascensia Diabetes Care Italy S.r.l.
Via Varesina, 162
20156 Milano – Italia
800608368
www.ascensia.com/eversense

Netherlands
Ascensia Diabetes Care Netherlands B.V.
Vermogenweg 107
3641 SR Mijdrecht
Nederland
0800 235 22 937
www.ascensia.com/eversense

Norway
Ascensia Diabetes Care Norway AS
Strandveien 50
1366 Lysaker
Norge
Kundeservice: +47 67 12 28 00
www.ascensia.com/eversense

Poland
Ascensia Diabetes Care Poland Sp. z o.o.
Aleje Jerozolimskie 92
00-807 Warszawa
Polska
+48 22 372 7220
www.ascensia.com/eversense

Spain
Ascensia Diabetes Care Spain, S.L.
WTC Almeda Park Edificio 6, 4ª Planta.
Plaça de la Pau s/n
08940 Cornellà de Llobregat
Barcelona, España
900 100 117
www.ascensia.com/eversense

Sweden
Ascensia Diabetes Care Sweden AB
Gustav III Boulevard 34, plan 4
169 73 Solna
020-83 00 84
www.ascensia.com/eversense

Switzerland
Ascensia Diabetes Care Switzerland AG
Peter Merian-Strasse 90
CH-4052 Basel
061 544 79 90
www.ascensia.com/eversense

MKT-001513 Rev 1

Disclaimer

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see https://global.eversensediabetes.com/safety-info.

The Eversense®XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal procedures are performed by a health care provider. The Eversense XL CGM System is a prescription device; patients should talk to their health care provider to learn more. For important safety information, see global.eversensediabetes.com/safety-info.